Compare PRCH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | CSTL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.9M | 806.3M |
| IPO Year | 2019 | 2019 |
| Metric | PRCH | CSTL |
|---|---|---|
| Price | $11.05 | $24.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $18.63 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 2.2M | 269.9K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,414,000.00 | $344,229,000.00 |
| Revenue This Year | $4.15 | $2.42 |
| Revenue Next Year | $17.05 | $12.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.18 | 3.66 |
| 52 Week Low | $6.36 | $14.59 |
| 52 Week High | $19.44 | $44.28 |
| Indicator | PRCH | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 74.05 | 48.34 |
| Support Level | $8.93 | $21.77 |
| Resistance Level | $16.67 | $26.20 |
| Average True Range (ATR) | 0.71 | 1.01 |
| MACD | 0.35 | 0.18 |
| Stochastic Oscillator | 88.38 | 63.58 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.